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To the Editor: Mycoplasma pneumoniae is a major 
cause of respiratory infections among children and young 
adults and is responsible for up to 40% of all community-
acquired pneumonia. In 2011, an epidemic of M. pneu-
moniae infection was reported in several countries in Eu-
rope and Asia and in Israel that primarily involved adhesin 
P1 type 1 strains and only a few P1 type 2 strains (1,2). The 
spread of M. pneumoniae was polyclonal (1–3), except in 
a few semiclosed settings, such as schools (4). Recently, 
a new adhesin P1 type 2 variant, named 2c, was reported 
(5,6) and accounted for 8.3% of 96 M. pneumoniae–posi-
tive samples in Germany (7).
In 2013, an increase in the number of community-
acquired pneumonia cases was reported in children and 
their adult contacts from 2 towns in Russia separated 
by 45 km, Ozerniy and Duchovshina, during Janu-
ary–March and October–November, respectively. To 
characterize the outbreak in Ozerniy, we collected 13 
throat swabs from 9 symptomatic children and 4 asymp-
tomatic adults who were the parents or grandparents of 
the affected children. All children attended the same 
school and were treated in the same district hospital as 
inpatients or outpatients. In Duchovshina, throat swab 
samples were collected from 17 children and 2 adults. 
The children attended the same school, and the pre-
school-aged children visited the same daycare center 1 
km away. One adult patient was the first aid driver who 
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transported the children to the hospital. The other adult 
patient was a community center worker who spent time 
with the children. In both cities, the symptomatic patients 
received β-lactams as initial therapy before testing.
All specimens were processed in the laboratory of mo-
lecular diagnostics of the Smolensk State Medical Acad-
emy (Smolensk Russia). Nucleic acids were extracted 
by using the DNA-sorb-AM nucleic-acid extraction kit 
(InterLabService, Moscow, Russia), and M. pneumoniae 
was subsequently detected by using the AmpliSens My-
coplasma pneumoniae/Chlamydophila pneumoniae-FRT 
PCR kit (InterLabService). Two M. pneumoniae molecular 
typing methods, adhesin P1 typing and multilocus variable-
number tandem-repeat analysis (MLVA), were performed 
as previously described (1,5,7). Macrolide resistance-asso-
ciated mutations were searched using real-time PCR and 
melting curve analysis (1).
The M. pneumoniae isolates from the specimens 
collected in Ozerniy were all adhesin P1 type 2c and be-
longed to 4 distinct MLVA types, 1 of which, MLVA type 
73563, has not been previously reported (Table). With-
out including the instable MPN1 marker (8), we observed 
only 2 MLVA types. The 19 M. pneumoniae isolates from 
the specimens collected in Duchovshina also were all P1 
type 2c, and all belonged to the same MLVA type, 43562 
(type M). No macrolide resistance–associated mutation 
was observed in any city. 
For comparison purposes, because no previous data re-
garding M. pneumoniae molecular epidemiology in Russia 
were available, we retrospectively characterized 29 speci-
mens, not from an outbreak, that were previously randomly 
collected for community-acquired pneumonia etiologic 
studies during October 2006–October 2007 and February–
October 2010 by the laboratory of Smolensk State Medical 
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Table. Characteristics of 61 Mycobacterium pneumoniae–positive respiratory tract specimens collected in Ozerniy and Duchovshina, 
Russia* 
City or region 
and specimen 
designation 
Sample 
source 
Patient 
age, y 
Hospitalization 
status 
Respiratory 
clinical 
syndrome 
Date of 
collection 
MLVA 
type† 
MLVA type 
without 
MPN1‡ 
PCR-
RFLP 
type 
Macrolide 
resistance 
genotype 
Ozerniy          
 38795 Throat swab 12 Inpatient Pneumonia 2013 Feb 15 53562 (S) 3562 2c Wild type 
 38796 Throat swab 10 Inpatient Pneumonia 2013 Feb 15 73562 (Y) 3562 2c Wild type 
 38799 Throat swab 10 Inpatient Pneumonia 2013 Feb 15 73563 3563 2c Wild type 
 38812 Throat swab 9 Inpatient Pneumonia 2013 Feb 15 73562 (Y) 3562 2c Wild type 
 38814 Throat swab 11 Inpatient Pneumonia 2013 Feb 15 73562 (Y) 3562 2c Wild type 
 38941 Throat swab 33 Outpatient Asymptomatic 2013 Feb 20 73563 3563 2c No amp 
 38945 Throat swab 10 Inpatient Pneumonia 2013 Feb 20 73563 3563 2c No amp 
 38946 Throat swab 10 Inpatient Pneumonia 2013 Feb 20 73563 3563 2c Wild type 
 38960 Throat swab 33 Outpatient Asymptomatic 2013 Feb 20 73563 3563 2c Wild type 
 38962 Throat swab 51 Outpatient Asymptomatic 2013 Feb 20 73562 (Y) 3562 2c Wild type 
 39042 Throat swab 9 Inpatient Pneumonia 2013 Feb 25 73562 (Y) 3562 2c Wild type 
 39048 Throat swab 64 Outpatient Asymptomatic 2013 Feb 25 63562 (V) 3562 2c Wild type 
 39293 Throat swab 8 Inpatient Pneumonia 2013 Mar 7 73562 (Y) 3562 2c Wild type 
Duchovshina          
 43593 Throat swab 13 Inpatient Pneumonia 2013 Oct 18 43562 (M) 3562 2c Wild type 
 43596 Throat swab 15 Outpatient Pneumonia 2013 Oct 18 43562 (M) 3562 2c Wild type 
 43597 Throat swab 12 Inpatient Pneumonia 2013 Oct 18 43562 (M) 3562 2c Wild type 
 43692 Throat swab 5 Inpatient Pneumonia 2013 Oct 22 43562 (M) 3562 2c Wild type 
 43693 Throat swab 10 Inpatient Pneumonia 2013 Oct 23 43562 (M) 3562 2c Wild type 
 43694 Throat swab 9 Inpatient Pneumonia 2013 Oct 22 43562 (M) 3562 2c Wild type 
 43695 Throat swab 13 Inpatient Pneumonia 2013 Oct 23 43562 (M) 3562 2c Wild type 
 43804 Throat swab 9 Inpatient Pneumonia 2013 Oct 27 43562 (M) 3562 2c Wild type 
 43805 Throat swab 6 Inpatient Pneumonia 2013 Oct 27 43562 (M) 3562 2c Wild type 
 43806 Throat swab 14 Inpatient Pneumonia 2013 Oct 27 43562 (M) 3562 2c Wild type 
 43843 Throat swab 6 Inpatient Pneumonia 2013 Oct 30 43562 (M) 3562 2c Wild type 
 43888 Throat swab 58 Outpatient Pneumonia 2013 Oct 31 43562 (M) 3562 2c Wild type 
 43890 Throat swab 4 Inpatient Pneumonia 2013 Oct 31 43562 (M) 3562 2c Wild type 
 43919 Throat swab 41 Outpatient Pneumonia 2013 Nov 1 43562 (M) 3562 2c Wild type 
 43989 Throat swab 10 Inpatient Pneumonia 2013 Nov 6 43562 (M) 3562 2c Wild type 
 43990 Throat swab 13 Inpatient Pneumonia 2013 Nov 6 43562 (M) 3562 2c Wild type 
 43991 Throat swab 8 Inpatient Pneumonia 2013 Nov 6 43562 (M) 3562 2c Wild type 
 44174 Throat swab 10 Inpatient Pneumonia 2013 Nov 14 43562 (M) 3562 2c Wild type 
 44176 Throat swab 8 Inpatient Pneumonia 2013 Nov 14 43562 (M) 3562 2c No amp 
*MLVA, multilocus variable-number tandem-repeat; no amp, no amplification with the real-time PCR used to detect 23S rRNA mutations associated with 
macrolide resistance (1); RFLP, restriction fragment length polymorphism. An expanded version of this table is available online at 
http://wwwnc.cdc.gov/EID/article/22/2/15-1349-T1.htm. 
†The profiles are named according to a string of allele numbers in order of MPN1, MPN13, MPN14, MPN15, and MPN16 markers showing the number of 
repeats at each locus. When available, the naming according to Degrange et al. is shown in parentheses (1). 
‡The profiles are named according to a string of allele numbers in order of MPN13, MPN14, MPN15 and MPN16 markers showing the number of repeats 
at each locus. The instable MPN1 marker (8) was removed. 
 
Academy (Table). Of these specimens, 12 (41%) were P1 
type 1, 15 (52%) were P1 type 2a, and only 2 (7%) were 
P1 type 2c. A polyclonal distribution with 8 distinct MLVA 
types was observed, with the MLVA type M representing 
11 (38%) of the identified MLVA types. Without the MPN1 
marker, 3 MLVA types were observed. No macrolide re-
sistance–associated mutation was detected, similar to what 
was observed in the 32 specimens collected in 2013. This 
finding is consistent with the low prevalence of macrolide 
resistance reported in northern Europe (6,7).
We report 2 outbreaks of M. pneumoniae infections 
that occurred in the first and last quarter of 2013 in western 
Russia (Smolensk region). Despite the high predominance 
of P1 type 1 strains reported in the recent literature (1,2,7), 
these 2 outbreaks, reported in semiclosed settings involved 
only the newly described P1 type 2c variant; 1 outbreak 
represented a monoclonal phenomenon. In the Smolensk 
region, the circulation of both type 1 and 2 strains was 
observed a few years before the outbreak; most of these 
strains were P1 type 2a variants, and only a minority were 
type 2c variants, suggesting that the new type 2c variant 
had spread throughout this region of Russia since at least 
2006. In other parts of the world, a switch between type 1 
and type 2 strains might be occurring. Indeed, in the United 
States, P1 type 1 isolates predominated before 2010 but 
dropped to 50% of isolates in 2013, and type 2 and type 2 
variant strains increased (9). This cyclic pattern of type 1 or 
type 2 predominance in the population has previously been 
reported (10).
In conclusion, we detected no macrolide resistance in 
western Russia. The P1 type 2c variant spread throughout 
this region and can be responsible for monoclonal out-
breaks. The epidemiologic monitoring of M. pneumoniae 
P1 types will assess the potential switch to P1 type 2 in the 
United States and other parts of the world and detect the 
possible emergence of the P1 type 2c variant.
This study was supported by internal funding.
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To the Editor: The 2014–2015 outbreak of Ebola 
virus disease (EVD) in West Africa was unprecedented 
in scale and scope. During the outbreak, 11 patients with 
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